ArticleCell reports. Medicine2026
Development and validation of a 5mC-based prognostic model for lung adenocarcinoma survival.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) exhibits marked prognostic heterogeneity. Existing methylation-based prognostic models lack robustness, accuracy, or external validation, limiting their clinical utility. We develop MethPro-LUAD, a prognostic model based on eight 5-methylcytosine features, using TCGA-LUAD data (training, N = 269; testing, N = 180), and validate the model across two independent hospital cohorts (Beijing, N = 195; Nanjing, N = 88) and two external GEO datasets (N = 82 and N = 155) to ensure its generalizability and effectiveness. MethPro-LUAD stratifies patients into high- and low-risk groups, with high-risk individuals consistently showing significantly shorter overall survival across all cohorts. In addition, the model's predictive performance remains robust in subgroups defined by age, sex, stage, and EGFR mutation and in disease-free survival analyses. Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.